Current Studies

Canadian Food Allergy Immunotherapy (CAN-FAIT) Research Collaboration and Registry

CAN-FAIT (previously called Canadian Preschool Peanut Oral Immunotherapy or CPP-OIT) was founded in 2017 with the goal of developing and implementing peanut OIT protocols in real patients, outside of clinical trials. The registry began with a small number of preschool patients, 0-5 years of age who were offered peanut OIT. Over the years, the number of patients offered OIT to peanut, as well as other foods like tree nuts, sesame, and others, has skyrocketed, and the registry now contains data on almost 2,500 patients and growing. The CAN-FAIT group has published numerous papers on safety and effectiveness of OIT, as well as protocols, patient flowsheets, and more, so that other allergists can offer OIT in their community practice with ease. We are currently working on publications describing psychosocial outcomes of patients undergoing OIT, as well as a new study to understand long-term adherence to OIT. Our group continues to grow each year with members representing most of the Canadian provinces, as well as a growing number of international collaborators from Hong Kong, Denmark, and United Arab Emirates.

Click below to view a growing list of publications emanating from this registry. 

Publications

• Soller L, Abrams EM. Carr S, Kapur S, Rex GA, Leo S, Lidman PG, Yeung J, Vander Leek TK, McHenry M, Wong T, Cook VE, Hildebrand KJ, Gerstner TV, Mak R, Lee NJ, Cameron SB, Chan ES. First real-world safety analysis of preschool peanut oral immunotherapy.  JACI: IP 2019; 7(8): 2759-2767.e5.
   
• Soller L, Abrams EM, Carr S, Kapur S, Rex GA, Leo S, McHenry M, Vander Leek TK, Yeung J, Cook VE, Wong T, Hildebrand KJ, Mak R, Gerstner TV, Cameron SB, Chan ES. First Real-World Effectiveness Analysis of Preschool Peanut Oral Immunotherapy. JACI: IP 2021; 9(3): 1349-1356.
   
• Soller L, Carr S, Kapur S, Rex GA, McHenry M, Cook VE, Leo S, Wong T, Vander Leek TK, Gerstner TV, Yeung J, Abrams EM, Mak R, Hildebrand KJ, Erdle SE, Cameron SB, Chan ES. Real-world peanut OIT in infants may be safer than non-infant preschool OIT and equally effective. JACI: IP 2022; 10(4):1113-1116.
   
• Chua G, Greenhawt M, Shaker M, Soller L, Abrams E, Cameron S, Cook V, Erdle S, Flesicher D, Mak R, Vander Leek T, Chan E. The Case for Prompt Salvage Infant Peanut Oral Immunotherapy Following Failed Primary Prevention. JACI: IP 2022; 10(10): 2561-2569.
   
• Chua G, Greenhawt M, Shaker M, Soller L, Abrams E, Cameron S, Cook V, Erdle S, Flesicher D, Mak R, Vander Leek T, Chan E. Real-world data are critical for the implementation of preschool food allergen immunotherapy. JACI IP 2023; 11(8): 2624-2625.
   
• Chua G, Chan E, Invik R, Soller L, Avinashi V, Erdle S, Wong T, Cook V, Mak R, Cameron S. How We Manage Gastrointestinal Symptoms During Oral Immunotherapy Through a Shared Decision-Making Process—A Practical Guide for the Community Practitioner. JACI: IP 2023; 11(4): 1049-1055.
   
• Karunakaran D, Chan ES, Zhang Q, Bone J, Carr S, Kapur S, Rex G, McHenry M, Cameron S, Cook V, Leo S, Wong T, Gerstner T, Yeung J, Abrams E, Mak R, Erdle S, Soller L. Risk factors associated with safety of preschool peanut oral immunotherapy. JACI: Global 2023; 2(2).
   
• Erdle S, Cook V, Cameron S, Yeung J, Kapur S, McHenry M, Chan E, Mak R, Rex G, Wong T, Soller L. Real-world Safety Analysis of Preschool Tree Nut Oral Immunotherapy. JACI: In Practice 2023; 11(4): 1177-1183.
   
• Soller L, Williams BA, Mak R, Wong T, Erdle SE, Chomyn A, Tetreault B, Morrison K, Gaudet L, Chan ES. Safety and Effectiveness of Bypassing Oral Immunotherapy Buildup With an Initial Phase of Sublingual Immunotherapy for Higher-Risk Food Allergy. JACI: IP 2024; 12(5): 1283-1296.
   
• Chua G, Soller L, Kapur S, McHenry M, Rex G, Cook V, Cameron S, Chan E, Yeung J, Erdle S. Real-world safety and effectiveness analysis of low-dose preschool sesame oral immunotherapy. JACI: Global 2024; 3(1).
   
• Williams BA, Guo Y, Soller L, Chan ES, Pratap-Singh, A. Total protein content and in vitro protein penetration rates of sublingual immunotherapy preparations. Annals 2024; 133(6):723-735.

FAIT Program

The FAIT Program is a UBC/BCCH research program developing and delivering cutting-edge food allergy treatments for BC families. The FAIT Program is a 100% virtual, nurse-led, program. Participants in the FAIT Program are invited to participate in the CAN-FAIT Registry. To be eligible to enroll in the FAIT program, you must be a current patient at the BCCH allergy clinic. Please click here for information on how to get a referral to the BCCH allergy clinic.

FAIT Biobanking Study

Patients who are part of the FAIT program at UBC/BCCH are invited to participate in the FAIT Biobank Study. Similar to the CAN-FAIT registry, which houses data, the Biobank houses samples, like blood, urine, hair, and more. For the FAIT Biobank project, we are only collecting blood samples. Please note, this study is for patients at UBC/BCCH only

Clinical Trials

The BCCH allergy clinic is a clinical trial site participating in various studies of new food allergy treatments. 

Past/current clinical trials 

Sponsor: DBV Technologies
Study Titles: Pepites, PEOPLE, Realise, EPITOPE, VITESSE
Intervention: Peanut “patch”

Upcoming clinical trials

Sponsor: ALK Abello
Study Title: ALLIANCE
Intervention: Peanut “tablet” aka sublingual immunotherapy

Please email allergyresearch@bcchr.ca if you would like to be considered for any of the above research studies.